Genito-Urinary Cancer
35
11
20
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.7%
2 terminated out of 35 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (35)
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Parametric PET of Genitourinary Cancer
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Discharge Medication Use Post-Operatively in GU Cancer Patients
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Integrated Molecular Profiling in Advanced Cancers Trial
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial